132 related articles for article (PubMed ID: 1494591)
1. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
[TBL] [Abstract][Full Text] [Related]
2. Reversible monoamine oxidase-A inhibitors in panic disorder.
Bakish D; Saxena BM; Bowen R; D'Souza J
Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
[TBL] [Abstract][Full Text] [Related]
3. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.
van Vliet IM; Westenberg HG; Den Boer JA
Psychopharmacology (Berl); 1993; 112(4):483-9. PubMed ID: 7871061
[TBL] [Abstract][Full Text] [Related]
4. The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia.
Bakish D
J Clin Psychopharmacol; 1994 Feb; 14(1):74-5. PubMed ID: 8151007
[No Abstract] [Full Text] [Related]
5. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
Fritze J; Becker T; Ziegler V; Laux G; Riederer P
Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
Schiwy W; Heath WR; Delini-Stula A
J Neural Transm Suppl; 1989; 28():33-44. PubMed ID: 2677240
[TBL] [Abstract][Full Text] [Related]
7. Reversible monoamine oxidase-A inhibitors in resistant major depression.
Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
[TBL] [Abstract][Full Text] [Related]
8. Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine.
Volz HP; Heimann H; Bellaire J; Laux G; Möller HJ
Pharmacopsychiatry; 1994 Jul; 27(4):152-8. PubMed ID: 7972347
[TBL] [Abstract][Full Text] [Related]
9. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine.
Kennedy SH; Goldbloom DS; Ralevski E; Davis C; D'Souza JD; Lofchy J
J Clin Psychopharmacol; 1993 Dec; 13(6):415-22. PubMed ID: 8120155
[TBL] [Abstract][Full Text] [Related]
11. Reversible monoamine-A inhibitors in panic disorder.
Bakish D
Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():432A-433A. PubMed ID: 1498904
[No Abstract] [Full Text] [Related]
12. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
[TBL] [Abstract][Full Text] [Related]
13. Reversible monoamine oxidase-A inhibitors in social phobia.
Liebowitz MR; Schneier F; Gitow A; Feerick J
Clin Neuropharmacol; 1993; 16 Suppl 2():S83-8. PubMed ID: 8313403
[TBL] [Abstract][Full Text] [Related]
14. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
Norman TR; Burrows GD
J Neural Transm Suppl; 1989; 28():53-63. PubMed ID: 2677243
[TBL] [Abstract][Full Text] [Related]
15. Brofaromine--a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings.
Möller HJ; Wendt G; Waldmeier P
Pharmacopsychiatry; 1991 Mar; 24(2):50-4. PubMed ID: 1852792
[TBL] [Abstract][Full Text] [Related]
16. An open trial of fluvoxamine therapy for panic disorder complicated by depression.
Spiegel DA; Saeed SA; Bruce TJ
J Clin Psychiatry; 1996; 57 Suppl 8():37-40; discussion 40-1. PubMed ID: 8698679
[TBL] [Abstract][Full Text] [Related]
17. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
Laux G; Classen W; Sofic E; Becker T; Riederer P; Lesch KP; Struck M; Beckmann H
J Neural Transm Suppl; 1990; 32():189-95. PubMed ID: 2089089
[TBL] [Abstract][Full Text] [Related]
18. Differential response patterns to MAO inhibitors and tricyclics.
Nies A
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):70-7. PubMed ID: 6376487
[TBL] [Abstract][Full Text] [Related]
19. Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.
Carter CS; Fawcett J; Hertzman M; Papp LA; Jones W; Patterson WM; Swinson RP; Weise CC; Maddock RJ; Denahan AQ
J Clin Psychiatry; 1995 May; 56(5):202-10. PubMed ID: 7737960
[TBL] [Abstract][Full Text] [Related]
20. Personality traits in social phobia, II: Changes during drug treatment.
Fahlén T
J Clin Psychiatry; 1995 Dec; 56(12):569-73. PubMed ID: 8530333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
